Publications

2026

  1. Yang S, Cress BF. Disarming a pathogen with programmable phage-derived particles. Trends Microbiol 2026;0. https://doi.org/10.1016/j.tim.2026.07.013.
  2. [Preprint] Selvakumar H, Noonan AJC, Rotman E, Alayouni M, Piya D, Maucourt F, Koderi Valappil S, Svab M, Orihuela B, Cowser G, Murray I, Bousliman C, Kazakov A, Deutschbauer AM, Roux S, Mimee M, Arkin AP, Mutalik VK. A comprehensive phage-bacteria interaction atlas links phage lineage and capsule serotype to genome-guided machine learning prediction in Klebsiella pneumoniae. bioRxiv 2026:2026.08.12.744533. https://doi.org/10.64898/2026.08.12.744533.
  3. Gittrich MR, Sanderson CM, Noel CM, Babusci E, Selbes SC, Svab M, Murray I, Bousliman C, Fofana A, Daboul A, Leopold J, Gonçalves de Melo A, Urvoy M, Moineau S, Mutalik VK, Sullivan MB. Cross-family and phage-specific gene requirements for Klebsiella infection revealed by scalable RB-TnSeq genetic screens. PLoS Genet 2026;22:e1012233. https://doi.org/10.1371/journal.pgen.1012233.
  4. [Preprint] Englert F, Valappil SK, Kubilius J, Jones SK Jr, Mutalik VK, Beisel CL, Patinios C. Targeted DNA nicking enables efficient, single-step and counterselection-free editing of bacteriophage genomes. bioRxiv 2026:2026.06.25.734514. https://doi.org/10.64898/2026.06.25.734514.
  5. Trinh J, Mutalik VK, Mageeney CM. Discovery, induction, and screening of prophages in clinical Acinetobacter baumannii isolates. Phage (New Rochelle) 2026. https://doi.org/10.1177/26416549261461823.
  6. [Preprint] Piya D, Noonan AJC, Selvakumar H, Alayouni M, Valappil SK, Maucourt F, Murray I, Svab M, Bousliman C, Heidenblut M, Orihuela B, Kazakov A, Carlson H, Yao Y, Smith E, Roux S, Deutschbauer A, Inman J, Arkin AP, Mutalik VK. Comprehensive interaction profiling and machine learning prediction of bacteriophage infectivity across clinically diverse Pseudomonas aeruginosa. bioRxiv 2026:2026.05.19.726084. https://doi.org/10.64898/2026.05.19.726084.
  7. [Preprint] Patel J, Swartz SE, Oromi-Bosch A, Yong L, LaTurner ZW, Demaray JE, Voelker A, Ono R, Vu P, Rao P, Luskin H, Andrade P, Cui ML, Mchedlishvili G, Hayes MM, Aluwihare N, Iglesias-Aguirre CE, MacKenzie EC, Rodriguez CI, Devkota S, Diamond S, Cress BF. Bridge recombinase enables versatile rewriting of bacterial genomes. bioRxiv 2026:2026.04.29.721476. https://doi.org/10.64898/2026.04.29.721476.
  8. González-Delgado A, Bonillo-Lopez L, Johnson MS, Knödlseder N, Ko C-C, Lekbach Y, Oh J-H, Selvakumar H, Wold MC, Yu Z, Aragón V, Gralnick JA, Güell M, Hatfull GF, Keitz BK, Koskella B, Mutalik VK, van Pijkeren J-P, Shipman SL. Genome editing of phylogenetically distinct bacteria using cross-species retron-mediated recombineering. Nat Biotechnol 2026:1–13. https://doi.org/10.1038/s41587-026-03076-6.
  9. [Preprint] Moriniere L, Noonan AJC, Kazakov A, Pena M, Svab M, Rivera-Lopez EO, Maucourt F, Johnson MS, Roux S, Koskella B, Deutschbauer AM, Dudley EG, Mutalik VK, Arkin AP. Enabling the prediction of phage receptor specificity from genome data. bioRxiv 2026:2026.04.02.716166. https://doi.org/10.64898/2026.04.02.716166.
  10. Mutalik VK, Inman JL, Chang H, Arkin A, Mao J-H. Phage therapy in oncology: opportunities for cancer prevention and treatment. Trends Mol Med 2026;0. https://doi.org/10.1016/j.molmed.2026.02.001.

2025

2024

Relevant Reading from 2023 and Earlier

Phage Foundry member names are bolded.